ABVC BioPharma up on receiving $460 mln worth shares under licensing deal
** Shares of ABVC BioPharma ABVC.O more than double to
$2.40 premarket
** Stock on track to hit its highest level since October
last year
** Co says, under the licensing deal, it received 46 million
shares valued at $10 per share from private company AiBtl
BioPharma
** Says it is the first milestone payment under a global
licensing agreement for ABVC's drugs to treat neurological
disorders
** Adds, that after this licensing payment, AiBtl becomes a
subsidiary of ABVC
** ABVC stock was down 81.4% in 2023
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
Recent news on ABVC Biopharma
See all newsBrief: ABVC Biopharma - Quarterly Period Ended September, 2025 Financial Statements Should Not Be Relied Upon
Brief: Abvc Biopharma Inc Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: ABVC Biopharma Concluded That Financial Statements For FY Ended Dec 31, 2023 Should No Longer Be Relied Upon Due To Errors In Financial Statements
Brief: ABVC Biopharma Inc On March 5, Leeds Chow Resigns As CFO Of Abvc Biopharma
Brief: ABVC Biopharma Secures $200,000 In First Cash Licensing Payment From Oncology Products Partner